title: The impact of chemotherapy on the lymphatic system in thoracic oncology.
abstract: Non-small-cell lung cancer remains the leading cause of cancer-related mortality in the United States and Europe. Most patients are diagnosed with metastatic disease for which chemotherapy remains the cornerstone of treatment. In non-metastatic disease, surgery is the most potentially curative therapeutic option, but its outcome is still poor, in particular for patients with lymph node involvement. Therefore, several randomized adjuvant/neoadjuvant trials using chemotherapy and/or radiotherapy investigated the possibility of increasing the overall survival of patients with surgically treated lung cancer. The findings are reviewed in this article.
authors.affiliation: Division of Medical Oncology, Sapienza-University of Rome, Viale Regina Elena, 324/00161-Rome, Italy. a-passaro@hotmail.it
authors.forename: Antonio
authors.initials: A
authors.lastname: Passaro
authors.forename: Patrizia
authors.initials: P
authors.lastname: Trenta
authors.forename: Davide
authors.initials: D
authors.lastname: Conte
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Campennì
authors.forename: Angelina
authors.initials: A
authors.lastname: De Benedetto
authors.forename: Enrico
authors.initials: E
authors.lastname: Cortesi
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D017024:Chemotherapy, Adjuvant / Q000379:methods; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008207:Lymphatic Metastasis; D008208:Lymphatic System; D015201:Meta-Analysis as Topic; D020360:Neoadjuvant Therapy / Q000379:methods; D016032:Randomized Controlled Trials as Topic